Document Detail


Cost-Effectiveness of Rivaroxaban in the Prevention of Venous Thromboembolism: A Canadian Analysis using the Ontario Ministry of Health Perspective.
MedLine Citation:
PMID:  22494267     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
ABSTRACT Objectives: A cost-effectiveness model for rivaroxaban evaluated the cost-effectiveness of prophylaxis with rivaroxaban (a once-daily, orally administered Factor Xa inhibitor) versus enoxaparin in the prevention of venous thromboembolism (VTE) after total hip replacement (THR) and total knee replacement (TKR). This Canadian analysis was conducted using the Ontario Ministry of Health perspective over a 5-year time horizon. The model combined clinical data and builds upon existing economic models. Methods: The model included both acute VTE (represented as a decision tree) and long-term complications (represented as a Markov process with 1-year cycles) phases. The model allowed VTE event rates, quality-adjusted life expectancy and direct medical costs to be estimated over a 5-year time horizon, based on current approved practice patterns in Canada. A number of one-way sensitivity analyses were performed on the baseline assumptions, including a comparison of rivaroxaban with dalteparin, and probabilistic sensitivity analyses were performed to address any uncertainty concerning model inputs. Results: When comparing equal durations of therapy, rivaroxaban dominated enoxaparin in the prevention of VTE events in patients undergoing THR and TKR, providing more benefit at a lower cost. Rivaroxaban was cost-effective when comparing 35 days' prophylaxis with 14 days' prophylaxis with enoxaparin following THR. One-way and probabilistic sensitivity analyses demonstrated that the results of the economic analysis were robust to variations in key inputs. Rivaroxaban remained dominant during one-way sensitivity analyses comparing rivaroxaban with dalteparin after THR or TKR. Limitations: Although clinical trial data were used in the prophylaxis module, assumptions and values used in the post-prophylaxis and long term complication (LTC) modules were based on several different literature sources; it was not always possible to source Canadian data. Conclusions: This economic analysis suggests that the use of rivaroxaban for the prophylaxis of VTE after THR or TKR in Canada was cost-effective.
Authors:
Heather McDonald; Alex Diamantopoulos; Philip Wells; Michael Lees; Kerstin Folkerts; Fiona Forster; Jaithri Ananthapavan
Related Documents :
22824127 - Learning from errors in radiology: a comprehensive review.
16682437 - Equity of access to dialysis facilities in wales.
22118097 - Technical note: validation of methodology for characterization of feeding behavior in d...
21912687 - The nirs analysis package: noise reduction and statistical inference.
20868357 - In vivo experimental models of epilepsy.
15986157 - How to improve quality assurance in fluorometry: fluorescence-inherent sources of error...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-12
Journal Detail:
Title:  Journal of medical economics     Volume:  -     ISSN:  1941-837X     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Next Document:  Pseudo-Pulmonic Stenosis in Non-Hodgkin's Large B-cell Lymphoma.